Compare Docusign Inc (DOCU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs TransMedics Group Inc — how do they compare? Docusign Inc trades at $70.94 (market cap $13.35B), while TransMedics Group Inc trades at $80.47 (market cap $2.74B). The key difference: Docusign Inc is far larger — about 4.9× TransMedics Group Inc's market cap, and Docusign Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and TransMedics Group Inc for 24 Days on average.
| DOCU | TMDX | |
|---|---|---|
Market Cap | $13.35B | $2.74B |
Volume | 3,158,858 | 949,331 |
Sector | Technology | Health |
52-Week High | $73.14 | $150.42 |
52-Week Low | $41.75 | $61.99 |
Typical Hold Time | 71 Days | 24 Days |
Enterprise Value | $12.76B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $68.90, up 1.0% on the day, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue growth has accelerated to $2.98 billion in 2025, with net income surging to $1.07 billion. The company maintains strong profitability metrics, including a 79.49% gross margin and 17.8% ROE, while recent news highlights AI integration in contract processing and leadership in workflow software.
The outlook is supported by solid fundamentals and positive analyst sentiment, though valuation multiples like a P/E of 43.55 suggest premium pricing. Key risks include market saturation in e-signatures and insider selling activity. The consensus price target of $68.75 aligns closely with the current price, indicating a neutral near-term view with long-term growth potential from AI adoption.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
